Trial
NCT06590558
Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer
Phase IWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
National Cancer Institute (NCI)
Collaborators
—
Condition
Anatomic Stage III Breast Cancer AJCC v8
Intervention
Biopsy Procedure
Why stopped
Manually added per CS0177524- Weekly CTEP status report.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-07-03